Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Novel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomas.

Iyer AK, Lan X, Zhu X, Su Y, Feng J, Zhang X, Gao D, Seo Y, Vanbrocklin HF, Broaddus VC, Liu B, He J.

Cancer Res. 2011 Apr 1;71(7):2428-32. doi: 10.1158/0008-5472.CAN-10-3484. Epub 2011 Mar 29.

2.

The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma.

Iyer AK, Su Y, Feng J, Lan X, Zhu X, Liu Y, Gao D, Seo Y, Vanbrocklin HF, Courtney Broaddus V, Liu B, He J.

Biomaterials. 2011 Apr;32(10):2605-13. doi: 10.1016/j.biomaterials.2010.11.073. Epub 2011 Jan 20.

3.

Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment.

He J, Wang Y, Feng J, Zhu X, Lan X, Iyer AK, Zhang N, Seo Y, VanBrocklin HF, Liu B.

J Nucl Med. 2010 Mar;51(3):427-32. doi: 10.2967/jnumed.109.069492. Epub 2010 Feb 11.

4.

Novel, cysteine-modified chelation strategy for the incorporation of [M(I)(CO)(3)](+) (M = Re, (99m)Tc) in an α-MSH peptide.

Jiang H, Kasten BB, Liu H, Qi S, Liu Y, Tian M, Barnes CL, Zhang H, Cheng Z, Benny PD.

Bioconjug Chem. 2012 Nov 21;23(11):2300-12. doi: 10.1021/bc300509k. Epub 2012 Nov 8.

5.

PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.

Thakur ML, Aruva MR, Gariepy J, Acton P, Rattan S, Prasad S, Wickstrom E, Alavi A.

J Nucl Med. 2004 Aug;45(8):1381-9.

6.

Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts.

Tsuji AB, Sogawa C, Sugyo A, Sudo H, Toyohara J, Koizumi M, Abe M, Hino O, Harada YN, Furukawa T, Suzuki K, Saga T.

Nucl Med Biol. 2009 May;36(4):379-88. doi: 10.1016/j.nucmedbio.2009.01.018. Epub 2009 Mar 26.

PMID:
19423005
7.

SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate.

Müller C, Forrer F, Schibli R, Krenning EP, de Jong M.

J Nucl Med. 2008 Feb;49(2):310-7. doi: 10.2967/jnumed.107.045856. Epub 2008 Jan 16.

8.

A novel multivalent (99m)Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts.

Li C, Zhang Y, Wang L, Feng H, Xia X, Ma J, Yuan H, Gao B, Lan X.

Nucl Med Biol. 2015 Jun;42(6):547-54. doi: 10.1016/j.nucmedbio.2015.01.011. Epub 2015 Feb 7.

PMID:
25779037
9.

Biodistribution characteristics and SPECT imaging of (99m)Tc-RET and (99m)Tc-REG in human lung cancer xenografts.

Xie WH, Zhang B, Wang LH, Liu CY, Chang C, Lei B, Wu YW.

Cancer Biother Radiopharm. 2015 Apr;30(3):117-24. doi: 10.1089/cbr.2014.1765. Epub 2015 Feb 25.

PMID:
25714734
10.

Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma.

Bidlingmaier S, He J, Wang Y, An F, Feng J, Barbone D, Gao D, Franc B, Broaddus VC, Liu B.

Cancer Res. 2009 Feb 15;69(4):1570-7. doi: 10.1158/0008-5472.CAN-08-1363. Epub 2009 Feb 3.

11.

99mTc-labeled estradiol as an estrogen receptor probe: Preparation and preclinical evaluation.

Xia X, Feng H, Li C, Qin C, Song Y, Zhang Y, Lan X.

Nucl Med Biol. 2016 Jan;43(1):89-96. doi: 10.1016/j.nucmedbio.2015.09.006. Epub 2015 Sep 21.

PMID:
26466867
12.

Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.

Okarvi SM, Al Jammaz I.

Nucl Med Biol. 2010 Apr;37(3):277-88. doi: 10.1016/j.nucmedbio.2009.12.006. Epub 2010 Feb 10.

PMID:
20346867
13.

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.

J Nucl Med. 2004 Oct;45(10):1776-83.

14.

Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.

Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, Muyldermans S, Lahoutte T, Caveliers V.

FASEB J. 2011 Jul;25(7):2433-46. doi: 10.1096/fj.10-180331. Epub 2011 Apr 8.

PMID:
21478264
15.

Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies.

An F, Drummond DC, Wilson S, Kirpotin DB, Nishimura SL, Broaddus VC, Liu B.

Mol Cancer Ther. 2008 Mar;7(3):569-78. doi: 10.1158/1535-7163.MCT-07-2132. Epub 2008 Mar 4.

16.
17.

Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT.

Li F, Cheng T, Dong Q, Wei R, Zhang Z, Luo D, Ma X, Wang S, Gao Q, Ma D, Zhu X, Xi L.

Nucl Med Biol. 2015 Mar;42(3):256-62. doi: 10.1016/j.nucmedbio.2014.11.001. Epub 2014 Nov 13.

PMID:
25516099
18.

Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.

Jung KH, Lee KH, Paik JY, Ko BH, Bae JS, Lee BC, Sung HJ, Kim DH, Choe YS, Chi DY.

J Nucl Med. 2006 Dec;47(12):2000-7.

19.

(99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.

Liu Y, Lan X, Wu T, Lang J, Jin X, Sun X, Wen Q, An R.

Nucl Med Biol. 2014 Jul;41(6):450-6. doi: 10.1016/j.nucmedbio.2014.03.020. Epub 2014 Mar 29.

PMID:
24768147
20.

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.

Wild D, Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, Christofori G, Ell PJ, Mäcke HR.

J Nucl Med. 2010 Jul;51(7):1059-67. doi: 10.2967/jnumed.110.074914.

Supplemental Content

Support Center